Search Results
Diamyd Medical divests U.S. gene therapy company
STOCKHOLM--(BUSINESS WIRE)-- Regulatory News: Diamyd Medical AB has entered into an agreement for the sale of the U.S. subsidiary, Diamyd, Inc., involved in drug development primarily relating to the NTDDS platform with applications in pain and neuropathy among others